You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 144 No. 7, July 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Paper
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology, Other
 •Gastrointestinal/ Upper Foregut
 •Surgical Oncology
 •Prognosis/ Outcomes
 •Gastrointestinal Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

An Evaluation of 2537 Gastrointestinal Stromal Tumors for a Proposed Clinical Staging System

Charles E. Woodall III, MD, MSc; Guy N. Brock, PhD; Jie Fan, MS; Jerome A. Byam, MD; Charles R. Scoggins, MD, MBA; Kelly M. McMasters, MD, PhD; Robert C. G. Martin II, MD, PhD

Arch Surg. 2009;144(7):670-678.

Hypothesis  A gastrointestinal stromal tumor (GIST) staging system can be created with the Surveillance, Epidemiology and End Results (SEER) database.

Design  A review of records in the SEER database from 2537 patients with GISTs from June 1, 1977, through August 1, 2004.

Patients and Methods  Patients were compared using all available clinicopathologic factors, and a TGM (tumor, grade, metastasis) staging system was created according to these parameters. Survival data were analyzed using Kaplan-Meier methods, log-rank analyses, and Cox regression models.

Results  Median follow-up time was 21 months, 47.6% of patients were men, and the median age was 64 years; 5.0% had lymph node involvement, and 22.6% had distant metastasis. Tumor size (T1, ≤70 mm; T2, >70 mm; P <.001), grade (G1, grades I and II; G2, grades III and IV; P <.001), and the presence of metastases (M0, no; M1, yes; P <.001) did affect overall survival. When combined in a TGM staging system, grade and metastasis were the factors most predictive of survival.

Conclusions  A staging system for GISTs that provides valuable prognostic information was developed. Further work to refine this system and validate it with other data sets should be undertaken. Mitotic index and standardized reporting may provide additional prognostic information and should be recorded for all tumors so that the most accurate staging system can be created.


Author Affiliations: Division of Surgical Oncology, Department of Surgery, University of Louisville School of Medicine James Graham Brown Cancer Center (Drs Woodall, Byam, Scoggins, McMasters, and Martin), and Department of Bioinformatics and Biostatistics, University of Louisville School of Public Health and Information Sciences (Dr Brock and Mr Fan), Louisville, Kentucky.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.